

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A humanized antibody binding to CD47.
2. (Original) The humanized antibody of claim 1 wherein CD47 is human CD47.
3. (Currently amended) The humanized antibody of claim 1 ~~or 2~~ wherein the CDRs of the humanized antibody are derived from a mouse antibody.
4. (Currently amended) The humanized antibody of ~~any one of claims 1 to 3~~ claim 1 comprising any one of the sequence sets below:
 - (1) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 7;
 - (2) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 10;
 - (3) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 13;
 - (4) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 16;
 - (5) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 19
 - (6) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 22;
 - (7) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 30;
 - (8) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 37;

(9) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 40;

(10) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 43;

(11) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 46;

(12) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 49;

(13) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 52;

(14) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 57;

(15) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 64; and

(16) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 67.

5. (Currently amended) The humanized antibody of ~~any one of claims 1 to 3~~ claim 1 comprising any one of the sequence sets below:

(1) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 7;

(2) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 10;

(3) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 13;

(4) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 16;

(5) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 19;

(6) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 22;

(7) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 30;

(8) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 37;

(9) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 40;

(10) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 43;

(11) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 46;

(12) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 49;

(13) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 52;

(14) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 57;

(15) the sequence of aa 1-30 (FR1), the sequence of aa 36-49 (FR2), the sequence of aa 67-98 (FR3), and the sequence of aa 107-117 (FR4) of SEQ ID NO: 64; and

(16) the sequence of aa 1-23 (FR1), the sequence of aa 40-54 (FR2), the sequence of aa 62-93 (FR3), and the sequence of aa 103-112 (FR4) of SEQ ID NO: 67.

6. (Currently amended) The humanized antibody of ~~any one of claims 1 to 5~~ claim 1, which is a small antibody fragment.

7. (Original) The humanized antibody of claim 6, which is a diabody.

8. (Original) The humanized antibody of claim 7, which is a single-chain diabody.

9. (Currently amended) The humanized antibody of claim 7 ~~or 8~~, characterized in that a disulfide bond exists between diabody-forming fragments.

10. (Original) The humanized antibody of claim 9 characterized by:

(1) an antibody having the amino acid sequence of SEQ ID NO: 90; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

11. (Original) The humanized antibody of claim 9 characterized by:

(1) an antibody having the amino acid sequence of SEQ ID NO: 92; or

(2) an antibody having an amino acid sequence containing a deletion, addition or substitution of one or several amino acid(s) in the amino acid sequence of (1) and having CD47-binding activity.

12. (Original) A diabody antibody binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments.

13. (Original) The diabody antibody of claim 12 comprising any one of the sequence sets below:

(1) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 7;

(2) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 10;

(3) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 13;

(4) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 16;

(5) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 19

(6) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 22;

(7) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 30;

(8) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 37;

(9) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 40;

(10) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 43;

(11) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 46;

(12) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 49;

(13) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 52;

(14) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 57;

(15) the sequence of aa 31-35 (CDR1), the sequence of aa 50-66 (CDR2), and the sequence of aa 99-106 (CDR3) of SEQ ID NO: 64; and

(16) the sequence of aa 24-39 (CDR1), the sequence of aa 55-61 (CDR2), and the sequence of aa 94-102 (CDR3) of SEQ ID NO: 67.

14. (Original) A humanized antibody binding to CD47 comprising:

(1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO: 30; and

(2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO: 57.

15. (Original) A humanized antibody binding to CD47 comprising:

(1) a heavy chain variable region containing the sequence of aa 1-117 of SEQ ID NO:

64: and

(2) a light chain variable region containing the sequence of aa 1-112 of SEQ ID NO:

67.

16. (Original) An antibody binding to CD47 comprising any one of:

(1) the sequence of aa 1-234 of SEQ ID NO: 73;

(2) the sequence of aa 1-234 of SEQ ID NO: 74;

(3) the sequence of aa 1-483 of SEQ ID NO: 78; and

(4) the sequence of aa 1-483 of SEQ ID NO: 79.

17. (Currently amended) A gene encoding the antibody of ~~any one of claims 1 to 16~~
claim 1.

18. (Original) A vector containing the gene of claim 17.

19. (Original) A host cell containing the vector of claim 18.

20. (Original) A process for preparing an antibody, comprising the step of culturing
the host cell of claim 19.

21. (Currently amended) A therapeutic agent for hematological disorder, comprising
the antibody of ~~any one of claims 1 to 16~~ claim 1.

22. (Original) The therapeutic agent of claim 21 wherein the hematological disorder is
selected from leukemias such as acute myelocytic leukemia, chronic myelocytic leukemia,
acute lymphocytic leukemia, chronic lymphocytic leukemia, adult T-cell leukemia, multiple
myeloma, mixed leukemia, and hairy cell leukemia; malignant lymphoma (Hodgkin's disease,
non-Hodgkin's lymphoma), aplastic anemia, myelodysplastic syndromes, and polycythemia
vera.